Endocytic Pathways Used by Andes Virus to Enter Primary Human Lung Endothelial Cells

Cheng-Feng Chiang¹, Mike Flint¹, Jin-Mann S. Lin², Christina F. Spiropoulou¹*

¹ Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America, ² Chronic Viral Diseases Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

* css8@cdc.gov

Abstract

Andes virus (ANDV) is the major cause of hantavirus pulmonary syndrome (HPS) in South America. Despite a high fatality rate (up to 40%), no vaccines or antiviral therapies are approved to treat ANDV infection. To understand the role of endocytic pathways in ANDV infection, we used 3 complementary approaches to identify cellular factors required for ANDV entry into human lung microvascular endothelial cells. We screened an siRNA library targeting 140 genes involved in membrane trafficking, and identified 55 genes required for ANDV infection. These genes control the major endocytic pathways, endosomal transport, cell signaling, and cytoskeleton rearrangement. We then used infectious ANDV and retroviral pseudovirions to further characterize the possible involvement of 9 of these genes in the early steps of ANDV entry. In addition, we used markers of cellular endocytosis along with chemical inhibitors of known endocytic pathways to show that ANDV uses multiple routes of entry to infect target cells. These entry mechanisms are mainly clathrin-, dynamin-, and cholesterol-dependent, but can also occur via a clathrin-independent manner.

Introduction

ANDS virus (ANDV) is a major representative of the New World hantaviruses in the Americas. It causes hantavirus pulmonary syndrome (HPS) with case fatality rates as high as 40% [1, 2]. HPS is characterized by fever, muscle aches, and headaches, rapidly progressing to pulmonary edema due to microvascular leakage, and to respiratory failure or shock [3]. At present, ANDV is the only hantavirus shown to be capable of human-to-human transmission [4]. No effective vaccines or antiviral drugs exist for HPS.

Hantaviruses are divided into Old World hantaviruses, such as Hantaan virus (HTNV) and Puumala virus (PUUV), and New World hantaviruses like ANDV and Sin Nombre virus. Hantaviruses belong to the Bunyaviridae family, and have a tri-segmented, negative-sense, single-stranded RNA genome. The genome consists of S, M, and L segments encoding the nucleocapsid (N) protein, 2 glycoproteins (Gn and Gc) produced from a single precursor (GPC), and L protein (also known as RNA-dependent RNA polymerase, RdRp), respectively. Attachment of ANDV to
its receptor on host cells is mediated by the virus surface glycoproteins Gn and Gc. Virion uptake by the infected cells is followed by low pH-dependent fusion between the virus and the endosomal membranes, and the release of ribonucleocapsid cores into the cytoplasm [5].

Hantaviruses use integrins to enter host cells, and pathogenic hantaviruses like ANDV depend on integrin \( \beta_3 \) (ITB3) as their receptor [6–8]. Cell susceptibility to hantavirus, however, depends not only on the expression of ITB3 [9, 10]; other cellular factors, such as decay-accelerating factor (DAF1) and the receptor of complement C1q are also important in hantavirus entry [11–14]. In addition, integrin \( \beta_2 \) was recently identified as a receptor for HTNV and as responsible for hantavirus pathogenesis [15]. The precise roles of each of these factors in hantavirus cell entry are currently unclear, however.

After attaching to the cell membrane, viruses commonly use host endocytic pathways, such as clathrin-mediated endocytosis, caveolin-mediated endocytosis, and macropinocytosis to reach intracellular compartments. The major endocytic pathways can be distinguished on the basis of their differential sensitivity to chemical inhibitors [16]. Using such compounds, previous studies have shown that HTNV entry involves clathrin and dynamin, but not caveolin-mediated endocytosis [17, 18]. However, ANDV infection was shown to be independent of both clathrin- and caveolin-mediated endocytosis, suggesting that New and Old World hantaviruses differentially utilize host cytoskeletal components during their life cycles [18]. Recent reports have shown consistently that both HTNV and ANDV require cholesterol for cell entry, an indication of raft-dependent access [12, 19, 20].

Vascular endothelial cells are the primary targets of ANDV infection in humans [21], and infection in these cells leads to loss of capillary integrity [22]. To better simulate natural ANDV infection, we used primary human lung microvascular endothelial cells (HMVEC-L) to study ANDV cell entry. Identifying cellular factors required for ANDV entry into its human target cells is crucial for understanding how this virus functions, and the results would benefit future development of antiviral treatments for ANDV infection. To identify such factors, we conducted an siRNA screen that specifically targeted human genes required for endocytosis, intracellular vesicular transport, cell signaling, and cytoskeleton rearrangement. In addition, we used a panel of chemical inhibitors of endocytic pathways to further probe the mechanisms of ANDV entry.

**Materials and Methods**

**Cell lines, virus, and antibodies**

HMVEC-L (Lonza, Walkersville, MD, USA) were grown with EGM-2MV medium (Lonza) in cell culture flasks pre-coated with phosphate-buffered saline (PBS) containing 0.2% gelatin (Sigma-Aldrich, St. Louis, MO, USA). ANDV (strain Chile 9717869) was propagated in Vero-E6 cells (obtained from ATCC, Manassas, VA, USA) in a biosafety level 3 laboratory. Viral titers were determined using immunostaining as described previously [23]. Western blot analyses were used to validate siRNA knockdown of targeted genes, and were performed as described [23]. The antibodies used for western blotting were directed against ANDV Gc (1:2000 dilution; catalog no. H1808-60, US Biological, Swampscott, MA, USA), AP2M1 (1:1000; ab75995, Abcam, Cambridge, MA, USA), ARF6 (1:200; sc-7971, Santa Cruz Biotechnology, Santa Cruz, CA, USA), caveolin-1 (CAV1; 1:1000; 610058, BD Biosciences, San Jose, CA, USA), CDC42 (1:1000; PA1-092, Thermo Fisher Scientific, Rockford, IL, USA), clathrin heavy chain (CLTC; 1:500; MA1-065, Thermo Fisher Scientific, Rockford, IL, USA), dynamin-2 (DNM2; 1:2000; sc-166669, Santa Cruz), ITB3 (1:100; sc-365570, Santa Cruz), NSF (1:200; ab16681, Abcam), RAB5C (1:500; SAB4502559, Sigma-Aldrich), TSG101 (1:200; sc-7964, Santa Cruz), and \( \beta \)-actin (Sigma-Aldrich).
Screening the siRNA library

The siRNA library used here (ON-TargetPlus, catalog no. G-105500, Dharmacon, Lafayette, CO, USA) targets human endocytic and membrane trafficking-related genes. A total of 140 genes was targeted using 4 siRNAs pooled for each gene [24]. All transfections were performed in a 96-well plate format. A 0.5% (v/v) stock of transfection reagent (DharmaFECT 1) was prepared in Opti-MEM solution (Life Technologies) and incubated at 23°C for 5 min. An equal volume (10 μL) of transfection reagent stock was mixed with rehydrated siRNA in each well for 20 min at 23°C. Subsequently, 2 × 10^4 HMVEC-L in 80 μL of EGM-2MV were added to each well and incubated for 48 h to allow significant gene knockdown by siRNA. The final concentration of pooled siRNA was 50 nM. Cell viability assays were also performed in a duplicate experiment to monitor for any cell toxicity caused by siRNA transfection.

For screening purposes, after transfection with siRNA, ANDV was added to HMVEC-L at an MOI of 0.5. At 48 h post infection, the cells were fixed at -20°C in absolute methanol (Sigma-Aldrich) for 20 min. The cells were then subjected to a previously described immunolabeling assay [23]. Briefly, the cells were washed 3 times with PBS containing 0.1% v/v Tween-20 (PBS-T), blocked with 5% skim milk in PBS-T, and incubated at 37°C for 30 min. Plates were then washed with PBS-T, incubated with mouse monoclonal anti-PUUV N protein antibody (1:4000) for 30 min at 37°C, and washed as above. Plates were incubated with 1% H₂O₂ (Sigma-Aldrich) for 15 min at room temperature, and washed as above. Subsequently, goat anti-mouse IgG1-conjugated HRP (1:25,000; Southern Biotech, Birmingham, AL, USA) was added at 37°C for 30 min before washing as above. Signal was detected with chemiluminescent peroxidase substrate-3 (Sigma-Aldrich) on a Synergy HT Microplate Reader (Biotek, Broadview, IL, USA) using 0.1 s integration.

In addition to transfection reagent (DharmaFECT 1) alone, negative controls used were a non-targeting siRNA, RISC-free siRNA, and siRNA targeting the housekeeping genes cyclophilin B, lamin A/C, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (all from Dharmacon). As positive controls, we included siRNA specifically targeting ANDV genome segments S or L, which suppressed expression of ANDV N protein in HMVEC-L as described in [23]. The quality and reliability of the screening result was determined by Z factor (Z'), which describes the available signal window for an assay in terms of the total separation between negative and positive controls minus the error associated with each type of control [25]. It is defined as

\[ Z' = 1 - 3 \times \frac{\sigma_p + \sigma_n}{\mu_p - \mu_n} \]

where \( \sigma_p, \sigma_n, \mu_p, \) and \( \mu_n \) are the standard deviations (σ) and the averages (μ) of the positive (p) and negative (n) controls.

ANDV pseudovirion entry assays

An expression vector encoding the human codon-optimized ANDV GPC gene was synthesized (DNA2.0, Menlo Park, CA, USA), and HIV pseudoparticles bearing ANDV GPC were prepared as described previously [26]. Briefly, 1 × 10^6 293T-LentiX cells (Clontech, Mountain View, CA, USA) were co-transfected with plasmid DNA encoding the HIV genome containing the firefly luciferase gene (pNL4-3.Luc.R.E') and an expression vector encoding the vesicular stomatitis virus (VSV) G protein or ANDV GPC. The ratio of HIV plasmid to glycoprotein expression vector was 8:1. Pseudoparticles were harvested from the medium of 293T-LentiX cells 48 and 72 h post transfection, and supernatants were combined and filtered to remove
cellular debris. Pseudoparticle titers were determined on HMVEC-L cells using the LentiX provirus quantitation kit (Clontech). To measure ANDV glycoprotein-dependent entry, pseudoparticles were added to HMVEC-L cells and allowed to adsorb for 6 h. After this time, the inoculum was removed and replaced with phenol red-free EGM-2-MV medium (Lonza). Two days after infection, firefly luciferase levels were measured using the luciferase assay system (Promega, Madison, WI, USA).

**Chemical inhibitor studies**

HMVEC-L were incubated at 37°C in low-serum (1% FBS) EGM-2MV medium supplemented with the following inhibitors: dynasore (ab120192, Abcam), chlorpromazine (CPZ; C8138, Sigma-Aldrich), Pitstop 2 (ab120687, Abcam), methyl-β-cyclodextrin (MβCD; C4555, Sigma-Aldrich), 5-(N-ethyl-N-isopropyl) amiloride (EIPA; A3085, Sigma-Aldrich), LY294002 (S1105, Selleckchem), or cytochalasin D (C8273, Sigma-Aldrich). Cytotoxic effects of these inhibitors on HMVEC-L were determined using the CellTiter-Glo luminescent assay (Promega) according to the manufacturer’s instructions, and were expressed as cytotoxic concentrations for 20% of the cells (CC20). For inhibitor treatment prior to ANDV or pseudovirion infection (pre-treatment), cells were treated with inhibitor diluted in low-serum (1% FBS) EGM-2MV medium or with an equivalent amount of a DMSO vehicle control for 1 h, and ANDV (MOI = 0.5) or pseudoparticles (MOI = 1) was added to cells in medium containing fresh inhibitor. After 3 h (ANDV) or 6 h (pseudovirions), the inoculum was removed and replaced with fresh medium containing inhibitor. Two days after ANDV infection, the cells were fixed in methanol, washed, and stained with PUUV anti-N protein primary antibodies, followed by AlexaFluor 488-conjugated secondary antibodies (Life Technologies, Grand Island, NY, USA). Cell nuclei were counterstained with DAPI (1 μg/mL, Life Technologies), and the plates were then imaged on Operetta High Content Screening system (Perkin Elmer, Waltham, MA, USA) in wide-field fluorescence mode using the 20× long WD objective. Twenty fields per well were imaged and analyzed. Subsequent image analyses were performed on Harmony software (Perkin Elmer) based on counting DAPI-stained nuclei as total cell populations followed by texture analysis of AlexaFluor 488-stained cytoplasms to determine the number of virus-infected cells. In the case of pseudovirion infection, luciferase assays were performed as described above.

For inhibitor treatment after ANDV infection (post-treatment), virus was added to cells in media without inhibitor; inhibitor was added 3 h later. All subsequent procedures were performed as described above.

**Dextran and transferrin uptake assay**

HMVEC-L were incubated in ice-cold, low-serum (1% FBS) EGM-2MV medium for 30 min before inoculation with ANDV (MOI = 30) for 1 h at 4°C. The cells were washed with ice-cold PBS, and given ice-cold, low-serum EGM-2MV media containing 10 kDa dextran (250 μg/mL) or transferrin (100 μg/mL) conjugated to AlexaFluor 488 (Life Technologies); the cells were then incubated for 20 min on ice. Cells were transferred to 37°C for 15 or 30 min, and then washed 3 times with ice-cold 2 mM PBS glycine (pH 2) before fixing cells with 4% paraformaldehyde in PBS, permeabilizing in 0.1% Triton X-100 in PBS, and imaging for immunofluorescence. Briefly, cells were stained with polyclonal anti-ANDV primary antibodies and AlexaFluor 633-conjugated secondary antibodies (Life Technologies), and cell nuclei were counterstained with DAPI (1 μg/mL). The resulting coverslips were examined by confocal microscopy.
Results

A human membrane trafficking siRNA library screen identified genes required for ANDV infection in HMVEC-L

To elucidate the pathways involved in the ANDV infectious cycle and identify the cellular genes essential for this process, we screened a commercially available library of siRNAs directed against genes involved in cellular transport. This screen was performed using primary HMVEC-L, a physiologically relevant cell type for ANDV replication. HMVEC-L were transfected with siRNAs, and infected with ANDV (MOI = 0.5) 48 h later. Forty-eight hours post infection, the cells were fixed and ANDV N protein was detected using a cell-based enzymatic assay [23]. A Z’ factor above 0.5 was consistently calculated, confirming the quality of the assay. Cell viability assays performed on mock-infected cells demonstrated that none of the siRNA pools tested reduced cell viability by more than 20% (data not shown).

Of the 140 siRNAs screened, 55 inhibited ANDV infection in HMVEC-L, as determined by analysis of variance (ANOVA) with Bonferroni correction (Fig 1 and S1 Table). These genes are known to regulate several endocytic pathways, vesicular transport, cell signaling, cytoskeletal formation, and exocytosis (S2 Table). None of the siRNAs tested increased ANDV replication. Of the 55 identified genes, 9 were selected for further characterization, based on their previously described association with entry pathways of various viruses (Table 1).

Reducing expression of endocytic genes affects ANDV protein expression and virus release

We first used western blotting to assess the efficiency of knockdown mediated by each of the transfected siRNA pools. We found that siRNAs differed in knockdown efficiency, ranging from 57% to 100% (densitometry data not shown, and Fig 2). The effect of knocking down each cellular gene on ANDV replication was assessed by western blotting for the viral proteins N and Gc (Fig 3), and by determining the titers of virus released from the transfected and infected cells (Fig 4).

Several siRNA pools induced a dramatic reduction in ANDV protein expression and titers. These included siRNAs targeting DNM2 and CLTC, which reduced ANDV protein expression to undetectable levels (Figs 2A, 2B and 3A). Furthermore, siRNAs targeting CLTC reduced virus release from infected cells to nearly undetectable levels (Fig 4).

The knockdown of CAV1, a major scaffolding protein involved in caveolin-mediated endocytosis [27], was only partial (Fig 2D), so the role of caveolin in ANDV entry was unclear. Suppressing the small GTPase ARF6 (Fig 2F), which is involved in many aspects of vesicular trafficking and actin remodeling and is implicated in macropinocytosis [28, 29], did not significantly affect virus protein expression and titers (Figs 3C and 4). Similarly, knocking down the small GTP-binding protein CDC42 (Fig 2E), an upstream actin regulator involved in the formation of filopodia in macropinocytosis [30, 31], minimally reduced ANDV protein expression and titers (Figs 3B and 4). The apparent differences between the initial library screening and the results obtained in these experiments may reflect differences between the assays used, as well as variability in the extent of knockdown of the targeted genes.

Interestingly, knocking down AP2M1 (Fig 2C), a component of an accessory complex commonly associated with forming clathrin-coated pits on the plasma membrane [32], appeared to increase Gc and N protein levels in infected cells (Fig 3B). No reduction in N and Gc protein levels was detected after knocking down TSG101 (Fig 3F), but viral titers were reduced, suggesting that TSG101 does not affect entry or replication, but rather the subsequent assembly
Fig 1. Using an siRNA library to identify genes involved in Andes virus infection of primary human lung cells. Andes virus (ANDV)-infected primary human macrovascular endothelial lung cells (HMVEC-L) after siRNA administration (blue) were compared with a negative control set and are presented as the percentage of ANDV-infected cells treated with non-targeting siRNA (NT). The results are shown as averages (± SD) of 4 independent sets of experiments. Negative control set includes non-targeting siRNA, RISC-free siRNA, and siRNAs targeting GAPDH, cyclophilin B, and lamin A/C. siRNA pools against the ANDV N segment were used to demonstrate positive knockdown. ANDV infection (shown in red) is significantly decreased after siRNA knockdown (p < 0.05).

doi:10.1371/journal.pone.0164768.g001
and release of progeny virions. Overall, our data indicate that ANDV entry and replication in HMVEC-L is clathrin- and dynamin-dependent.

**ANDV pseudovirion entry in HMVEC-L cells**

To determine if the identified genes played a role in ANDV entry or in other steps of ANDV replication, we used HIV pseudotyped particles bearing the ANDV glycoprotein. We have shown previously that entry and consequent expression of the luciferase reporter gene from these particles are ANDV glycoprotein-dependent [33]. HIV pseudovirions bearing the VSV glycoprotein G were used as a control. HMVEC-L cells were transfected with the specific siRNAs described above, and then transduced with pseudovirions bearing ANDV GPC or VSV G; luciferase levels were measured 2 days after infection (Fig 5).

As expected, knocking down ITB3, (Fig 5 inset), a known receptor for pathogenic hantaviruses like ANDV [6, 7], inhibited luciferase expression after infection with ANDV pseudovirions but not with VSV pseudovirions (Fig 5). This confirms the utility of the pseudovirus system for studying ANDV glycoprotein-dependent entry. Knocking down DNM2, CLTC, and AP2M1, factors involved in clathrin-mediated endocytosis, reduced luciferase expression (Fig 5), consistent with a role for this pathway in ANDV glycoprotein-dependent entry. Interestingly, knocking down CDC42 or ARF6 suppressed luciferase expression after infection with ANDV pseudovirions (Fig 5), though not with wild-type ANDV virus (Fig 3).

**Chemical inhibition suggests that ANDV uses clathrin-dependent cell entry in HMVEC-L**

Next, we used a panel of chemical inhibitors of endocytosis to probe the endocytic pathways used by ANDV to enter primary HMVEC-L (Table 2). First, we tested the cytotoxic effects of
each inhibitor in HMVEC-L cells, and subsequently used concentrations of inhibitors that minimally impacted cell viability (<20% reduction). In general, these concentrations fell below those used in a previously published study on continuous cell lines [16]. Each chemical inhibitor was added either 1 h before or 3 h after virus infection, and was present during the course of the infection. Among the compounds that were found to inhibit ANDV infection was the dynamin inhibitor dynasore, which is required for the scission step that separates the vesicle from the plasma membrane (in clathrin- or caveolin-mediated endocytosis) or from the intracellular organelle (Table 2). Pitstop 2, which blocks clathrin-mediated endocytosis (Table 2, [34]), also significantly reduced ANDV infectivity (Fig 6). Pitstop 2 is known to specifically work through blocking protein binding to the N terminus of clathrin, although it can affect other nonspecific targets in the cell [35]. MβCD, which depletes cellular cholesterol (Table 2) and inhibits ANDV infection in Vero-E6 cells [19], also blocked ANDV infection of HMVEC-L. EIPA is a potent and specific inhibitor of the Na⁺/H⁺ exchange, and is frequently used as a specific inhibitor of macropinocytosis [36]. When added prior to infection, EIPA potently inhibited ANDV infection of HMVEC-L in a concentration-dependent fashion (Fig 6).

In general, adding the compounds after ANDV infection had less effect on infectivity, suggesting that these compounds affect virus entry. Pretreating HMVEC-L cells with CPZ, a
clathrin-mediated endocytosis inhibitor, and with PI3K inhibitor LY294002 did not inhibit virus entry (S1 Fig). Similarly, pretreating with cytochalasin D, a known inhibitor of actin polymerization, had no impact on ANDV infectivity in HMVEC-L (S1 Fig). However, HMVEC-L cells were extremely sensitive to cytochalasin D treatment, and even very low concentrations caused extensive cytopathic effect (S2 Fig).

To confirm that the effects of EIPA, dynasore, Pitstop 2, and MβCD were specific for ANDV glycoprotein-dependent entry, we tested the ability of these inhibitors to block the entry of pseudovirions bearing ANDV GPC (Fig 7). Pretreating cells with each compound caused a concentration-dependent reduction in infection (Fig 7), confirming that these compounds inhibit ANDV entry into HMVEC-L. Interestingly, some of the compounds were more cytotoxic during these experiments than in ANDV-infected cells.
Fig 4. Knocking down selected host proteins by siRNA decreases ANDV release. Plaque assays to determine titers of ANDV released by HMVEC-L infected with ANDV after transfection with gene-specific siRNA against DNM2, CLTC, AP2M1, CAV1, CDC42, ARF6, RAB5C, NSF, or TSG101, or with the non-targeting siRNA transfection control (NT). siRNAs were transfected into HMVEC-L at the concentration of 100 nM for 48 h, and cells were infected with ANDV (MOI = 0.5) for 48 h. Culture media were harvested, and plaque assays were performed in Vero-E6 cells. Viral plaques were stained and counted 5 days post-infection and expressed in focus forming unit (FFU)/mL, as shown on the y-axis of each panel. Results presented are the averages (± SD) of 4 experiments. Statistically significant differences compared to NT results at the same time points are shown with an asterisk (*; p < 0.05).

doi:10.1371/journal.pone.0164768.g004

Fig 5. siRNA profiling of selected genes required for recombinant ANDV pseudovirus infection. Gene-specific siRNA against integrin β3 (ITB3), DNM2, CLTC, AP2M1, CDC42, or ARF6, or the non-targeting siRNA transfection control (NT), were transfected into HMVEC-L at the concentration of 100 nM for 48 h. Cells were infected with pseudovirions (MOI = 1) for 48 h. All pseudovirions consisted of an HIV backbone with firefly luciferase, and were pseudotyped with ANDV GPC (ANDV) or vesicular stomatitis virus G protein (VSV). Effects of gene knockdown were measured by quantifying luciferase activity in the host genome. Solid bars represent ANDV, and open bars represent VSV. Luciferase activity is expressed as units relative to non-targeting siRNA control (% infection). The effect of ITB3-specific siRNA knockdown is shown in the inset. Results presented are the averages (± SD) of 10 experiments (n = 10), and significant decreases in pseudovirus infection (p < 0.05) after siRNA knockdown are shown with an asterisk (*).

doi:10.1371/journal.pone.0164768.g005
Altogether, these data suggest that ANDV uses clathrin- and cholesterol-dependent cell entry pathways, while inhibition with EIPA also implicates entry via a mechanism similar to macropinocytosis in HMVEC-L cells.

**ANDV partially co-localizes with both transferrin and fluorescent dextran molecules**

To further elucidate any possible role of macropinocytosis in ANDV entry into primary lung cells, we traced the internalization of ANDV and dextran, a fluorescent fluid phase marker [37]. HMVEC-L were inoculated with ANDV (MOI = 30), washed, and incubated with dextran conjugated to AlexaFluor 488 (Fig 8, top row) or with labeled transferrin (Fig 8, middle row). Confocal microscopy revealed that ANDV virions (shown in red) colocalized with dextran (green, Fig 8, top row). At 30 min post virus entry, large inclusions were observed when cells were co-stained for both virus antigen and dextran. We found that the ratio of those large inclusions to the punctate staining also observed intracellularly was approximately 1:1. The size of the larger inclusions was variable, but they were significantly bigger than the punctate staining. We do not know if the large inclusions are physiologically relevant at this point. The fact that they are not present at 15 min post entry (second row in the Fig 8) indicates that they are not virus aggregates created during virus stock preparation, but are areas of intracellular virus accumulation. These results suggest that ANDV can enter primary cells via multiple endocytotic mechanisms, including clathrin-dependent endocytosis, and possibly implicate macropinocytosis in virus entry.

**Discussion**

In the present study, we identified cellular pathways by which ANDV enters primary HMVEC-L, a physiologically relevant cell type. We initially used an siRNA library to identify important genes, and subsequently used chemical inhibitors of endocytosis to probe ANDV cell entry mechanisms. Our data indicate that ANDV enters primary human lung cells by clathrin-mediated endocytosis, though some evidence for an additional macropinocytosis-like entry mechanism was also found.

Viruses can use several pathways to enter cells, although many of them will preferentially use one pathway, depending on the cell type [38–42]. Hantavirus infection is a multi-step process initiated by cell surface attachment and followed by internalization of virions, converging toward the early endosome [5]. A previous study showed that pre-treatment with...
chlorpromazine or filipin did not significantly decrease ANDV infection, and concluded that
ANDV does not use either clathrin- or caveolin-mediated endocytosis to enter Vero-E6 cells
[18]. Another study showed that ANDV entry is inhibited by the cholesterol inhibitor mevasta-
tin in Vero-E6 cells, suggesting that entry may occur through endocytosis via lipid rafts [19]. In
addition to these seemingly contradictory findings, ITB3, a receptor for pathogenic

Fig 6. Productive ANDV infection in HMVEC-L depends on dynamin, cholesterol, and clathrin pathways.
HUMVEC-L viability (red lines) and level of ANDV infection (blue bars) when using varying concentrations of the
indicated inhibitors. For inhibitor pretreatment (Pre), HMVEC-L were treated with dynasore, MβCD, Pitstop 2, or
EIPA for 1 h before inoculating with ANDV (MOI = 1) in the presence of the inhibitor. For post-treatment (Post), cells
were infected with ANDV; after 3 h, virus was removed and media replaced with low-serum medium containing
inhibitor. Infection was assessed 16 h post infection by immunofluorescence assay. Percentages of infected and
viable cells were determined relative to untreated controls (UC). Results presented are the averages (± SD) of
triple experiments. Recombinant VSV virus (rVSV) infection was also used as a control (S3 Fig).
hantaviruses including ANDV, is internalized by both clathrin- and non-clathrin-dependent endocytosis [43, 44].

We found that cellular genes like DNM2 and CLTC were essential for ANDV entry into HMVEC-L, suggesting entry via clathrin-mediated endocytosis. These results were supported by inhibition of ANDV and pseudovirion infection by the chemical inhibitors dynasore and Pitstop 2.

CPZ is an antipsychotic agent that has been implicated in clathrin-mediated endocytosis because it blocks the interaction of AP2 with clathrin during the formation of clathrin-coated pits. However, CPZ can also bind to other proteins, including calmodulin, channel proteins, and other membrane proteins, and more recently has been shown to trigger autophagy without causing cell death [45]. Actually, treatment with CPZ did not inhibit ANDV infection, but rather enhanced ANDV infection (S1A Fig). A probable explanation for this result is that CPZ is known to induce cell autophagy, and ANDV utilizes autophagy for efficient replication [33, 46]. CPZ treatment is also known to inhibit virus entry in continuous cell lines, but not in a number of primary cell lines, particularly in HMVEC-L cells [38].

Unlike clathrin-dependent endocytosis, no single protein coat, cellular factor, chemical inhibitor, or feature defines macropinocytosis [16, 31]. Experimental criteria have been
recommended for determining whether a virus uses the macropinocytic pathway, with the caveat that the extent of entry through this pathway can differ with cell type [31]. Na\(^+\)/H\(^+\) exchangers, such as EIPA, are understood to be important indicators of viral entry by macropinocytosis, and we found that EIPA potently inhibited ANDV entry. Moreover, ANDV co-localized with high molecular weight dextran within intracellular vacuoles. Macropinocytosis can be a direct viral entry mechanism, or be used indirectly, by virions first binding to receptors in clathrin-coated pits, and then being enclosed by lamellipodia or circular ruffles to complete

Fig 8. Co-localization of ANDV with high molecular weight dextran and transferrin in HMVEC-L. Confocal images of HMVEC-L treated with high molecular weight dextran or transferrin and infected with ANDV. ANDV is shown in red and was stained with anti-ANDV polyclonal antibodies and AlexaFluor 633-conjugated secondary antibodies. Green represents 10 kDa dextran or transferrin conjugated to AlexaFluor 488. Host nuclei were stained blue with DAPI. Confocal images were taken 15 or 30 min post infection, as indicated. White arrows indicate co-localization of ANDV with dextran or transferrin. Arrowheads show areas of intracellular viral accumulation. Bar, 10 μm.

doi:10.1371/journal.pone.0164768.g008
the engulfing process [31]. Whether such sequential, coordinated actions between endocytic pathways act during ANDV entry remains to be elucidated.

Actin is required for clathrin-mediated endocytosis or macropinocytosis [47]. As mentioned earlier, treatment with EIPA, which can also induce reorganization of the actin structure [48], suppressed ANDV entry by these mechanisms. However, the actin polymerization inhibitor cytochalasin D had no impact on ANDV infectivity in HMVEC-L at the maximum concentration used (250 nM). The reason for these seemingly contradictory results is that cytochalasin D caused extensive cytotoxicity to HMVEC-L cells before reaching the concentrations of 2–3 μM known to be necessary to disrupt actin polymerization [49]. In addition to cytochalasin D, pretreating HMVEC-L cells with PI3K inhibitor LY294002 did not inhibit virus entry, also indicating that ANDV entry is PI3K-independent. These results are shown in S1 Fig.

Interestingly, knocking down macropinocytosis markers PAK-1 (Fig 1), CDC42 (Figs 3 and 4), and ARF6 (Figs 3 and 4) did not significantly reduce ANDV infection. However, another main marker of macropinocytosis, Rho GTPase RAC1, significantly contributed to ANDV infection, as shown in Fig 1. It is possible that when Rho GTPases like CDC42 are inhibited, other GTPases substitute their function. Knocking down genes encoding WASF2 and WASF3, members of the Wiskott-Aldrich syndrome protein family, also affected virus replication (Fig 1). These gene products form a multiprotein complex that links receptor kinases and GTPases with actin and ultimately facilitates non-clathrin mediated endocytosis.

While validating the involvement of endocytic genes identified in the initial siRNA library screening, we found that knocking down NSF and TSG101 had little effect on the expression of ANDV N and Gc proteins, but significantly reduced virus release, suggesting that these proteins are involved in viral assembly or budding, but not in entry or replication. These proteins, or their associated proteins, are thus potential cellular targets for anti-ANDV therapies.

In conclusion, our results suggest that ANDV can use clathrin-mediated endocytosis to enter a physiologically relevant host cell type. ANDV entry is also dynamin- and cholesterol-dependent. Additionally, a clathrin-independent pathway is involved; this pathway shares some features with macropinocytosis, but the exact mechanism remains to be determined. These pathways should be considered when designing antiviral therapies targeting the entry mechanism.

Supporting Information

S1 Fig. Effects of chlorpromazine, cytochalasin D, and LY294002 on ANDV infection in HMVEC-L. Viability curve (red line) and percentage of ANDV-infected HMVEC-L (blue bars) after treatment with indicated concentrations of (A) chlorpromazine, (B) cytochalasin D, or (C) LY294002. Cells were incubated with inhibitor for 1 h prior to ANDV infection (MOI = 1). After 3 h, virus was removed and replaced with low-serum medium containing inhibitor. ANDV presence was determined 16 h after infection by immunostaining the N protein. Viability and percentages of infected cells were calculated relative to untreated controls (UC). Results presented are the averages (± SD) of triplicate experiments.

(TIF)

S2 Fig. Cytotoxicity of cytochalasin D in HMVEC-L. Viability curve of HMVEC-L after treatment with indicated concentrations of cytochalasin D. Cells were incubated with inhibitor for 16 h before viability was determined relative to untreated controls (UC). Results presented are the averages (± SD) of triplicate experiments.

(TIF)
S3 Fig. Effects of Pitstop 2, EIPA, MβCD, dynasore, and chlorpromazine on recombinant VSV infection in HMVEC-L. Viability curve (red line) and percentage of rVSV-infected HMVEC-L (blue bars) after treatment with indicated concentrations of (A) Pitstop 2, (B) EIPA, (C) MβCD, (D) dynasore, or (E) chlorpromazine. Cells were incubated with inhibitor for 1 h prior to rVSV infection (MOI = 1). After 3 h, virus was removed and replaced with low-serum medium containing inhibitor. rVSV presence was determined 8 h after infection by the fluorescent intensity of GFP expressed from rVSV. rVSV was produced from Vero-E6 cells transfected with KeraFAST VSV-ΔG-GFP plasmid expression vectors and pseudotyped with VSV G. Viability and percentages of infected cells were calculated relative to untreated controls (UC). Results presented are the averages (± SD) of triplicate experiments.

(TIF)

S1 Table. Results of siRNA screening.

(DOCX)

S2 Table. Genes identified by siRNA library screening that affect ANDV infection of HMVEC-L.

(DOC)

S3 Table. Viral protein levels and ANDV release determined by western blotting and plaque assays, respectively.

(DOCX)

Acknowledgments

We thank Punya Ranjan for technical support on confocal microscopy. We are also grateful to Tatyana Klimova, Cesar Albariño, and C. Reynold Verret (Xavier University of Louisiana) for critical reading and helpful discussions during manuscript preparation. In addition, we acknowledge John Klena, Pierre Rollin, and Stuart Nichol for their support in this study. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Author Contributions

Conceptualization: CFC CFS.

Data curation: CFC.

Formal analysis: JSL.

Funding acquisition: CFS.

Investigation: CFC.

Methodology: CFC MF.

Project administration: CFS.

Resources: CFS.

Software: JSL CFC.

Supervision: CFS.

Validation: CFC.

Visualization: CFC.
References

1. Wells RM, Young J, Williams RJ, Armstrong LR, Busico K, Khan AS, et al. Hantavirus transmission in the United States. Emerg Infect Dis. 1997; 3: 361–365. doi: 10.3201/aid0030.970314 PMID: 9284382

2. Doyle TJ, Bryan RT, Peters CJ. Viral hemorrhagic fevers and hantavirus infections in the Americas. Infect Dis Clin North Am. 1998; 12: 95–110. PMID: 9494832

3. Enria DA, Briggler AM, Pini N, Lewis S. Clinical manifestations of New World hantaviruses. Curr Top Microbiol Immunol. 2001; 256: 117–134. PMID: 11217400

4. Padula PJ, Edelstein A, Miguel SD, Lopez NM, Rossi CM, Rabinovich RD. Hantavirus pulmonary syndrome outbreak in Argentina: molecular evidence for person-to-person transmission of Andes virus. Virology. 1998; 241: 323–330. doi: 10.1006/viro.1997.6976 PMID: 9499807

5. Vaheri A, Strandin T, Hepojoki J, Sironen T, Henttonen H, Makela S, et al. Uncovering the mysteries of hantavirus infections. Nat Rev Microbiol. 2013; 11: 539–550. PMID: 24020072

6. Gavrilovskaya IN, Shepley M, Shaw R, Ginsberg MH, Mackow ER. Beta3 integrins mediate the cellular entry of hantaviruses that cause respiratory failure. Proc Natl Acad Sci USA. 1998; 95: 7074–7079. PMID: 9618541

7. Matthys VS, Gorbunova EE, Gavrilovskaya IN, Mackow ER. Andes virus recognition of human and Syrian hamster beta3 integrins is determined by an L33P substitution in the PSI domain. J Virol. 2010; 84: 352–360. doi: 10.1128/JVI.01013-09 PMID: 19846530

8. Raymond T, Gorbunova E, Gavrilovskaya IN, Mackow ER. Pathogenic hantaviruses bind plexin-semaphorin-integrin domains present at the apex of inactive, bent alpha(v)beta(3) integrin conformers. Proc Natl Acad Sci USA. 2005; 102: 1163–1168. doi: 10.1073/pnas.0406743102 PMID: 15657120

9. Higa MM, Petersen J, Hooper J, Doms RW. Efficient production of Hantaan and Puumala pseudovirions for viral tropism and neutralization studies. Virology. 2012; 423: 134–142. doi: 10.1016/j.virol.2011.08.012 PMID: 22209230

10. Ray N, Whidby J, Stewart S, Hooper JW, Bertolotto-Ciarlet A. Study of Andes virus entry and neutralization using a pseudovirion system. J Virol Methods. 2010; 163: 416–423. doi: 10.1016/j.jvirmet.2009.11.004 PMID: 20034996

11. Popugaeva E, Witkowski PT, Schiegel M, Ulrich RG, Auste B, Rang A, et al. Dobrava-Belgrade hantavirus from Germany shows receptor usage and innate immunity induction consistent with the pathogenicity of the virus in humans. PLoS One. 2012; 7: e35587. doi: 10.1371/journal.pone.0035587 PMID: 22545121

12. Krautkramer E, Zeier M. Hantavirus causing hemorrhagic fever with renal syndrome enters from the apical surface and requires decay-accelerating factor (DAF/CDF5). J Virol. 2008; 82: 4257–4264. doi: 10.1128/JVI.02210-07 PMID: 18305044

13. Buranda T, Wu Y, Perez D, Jett SD, Bondul-Hawkins V, Ye C, et al. Recognition of decay accelerating factor and alpha(v)beta(3) by inactivated hantaviruses: Toward the development of high-throughput screening flow cytometry assays. Anal Biochem. 2010; 402: 151–160. doi: 10.1016/j.jab.2010.03.016 PMID: 20363206

14. Choi Y, Kwon YC, Kim SI, Park JM, Lee KH, Ahn BY. A hantavirus causing hemorrhagic fever with renal syndrome requires gC1qR/p32 for efficient cell binding and infection. Virology. 2008; 381: 178–183. doi: 10.1016/j.viro.2008.08.035 PMID: 18834607

15. Rafteny MJ, Lalwani P, Krautkmer E, Peters T, Scharffetter-Kochanek K, Kruger R, et al. Beta2 integrin mediates hantavirus-induced release of neutrophil extracellular traps. J Exp Med. 2014; 211: 1485–1497. doi: 10.1084/jem.20131092 PMID: 24889201

16. Ivanov AI. Exocytosis and endocytosis. Methods Mol Biol. 2008; 440: 15–33. doi: 10.1007/978-1-59745-178-9_2

17. Jin M, Park J, Lee S, Park B, Shin J, Song KJ, et al. Hantaan virus enters cells by clathrin-dependent receptor-mediated endocytosis. Virology. 2002; 294: 60–69. doi: 10.1006/viro.2001.1303 PMID: 1186265

18. Ramanathan HN, Jonsson CB. New and Old World hantaviruses differentially utilize host cytoskeletal components during their life cycles. Virology. 2008; 374: 138–150. doi: 10.1016/j.virol.2007.12.030 PMID: 18234268
19. Petersen J, Drake MJ, Bruce EA, Riblett AM, Wilen CB, et al. The major cellular sterol regulatory pathway is required for Andes virus infection. PLoS Pathog. 2014; 10: e1003911. doi: 10.1371/journal.ppat.1003911 PMID: 24516383

20. Kleinfelter LM, Jangra RK, Jae LT, Herbert AS, Stiles KM, et al. Haploid genetic screen reveals a profound and direct dependence on cholesterol for hantavirus membrane fusion. mBio. 2015; 6. doi: 10.1128/mBio.00801-15 PMID: 26126854

21. Borges AA, Campos GM, Morell ML, Souza RL, Aquino VH, Saggioro FP, et al. Hantavirus cardiopulmonary syndrome: immune response and pathogenesis. Microbes Infect. 2006; 8: 2324–2330. S1286-4579(06)00188-2 [pii] doi: 10.1016/j.micinf.2006.04.019 PMID: 16793309

22. Zaki SR, Greer PW, Coffield LM, Goldsmith CS, Nolte KB, Foucar K, et al. Hantavirus pulmonary syndrome. Pathogenesis of an emerging infectious disease. Am J Pathol. 1995; 146: 552–579. PMID: 7874439

23. Chiang CF, Albariño CG, Lo MK, Spiropoulos CF. Small interfering RNA inhibition of Andes virus replication. PLoS One. 2014; 9: e99764. doi: 10.1371/journal.pone.0099764 PMID: 24924189

24. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvoriha A. Rational siRNA design for RNA interference. Nat Biotechnol. 2004; 22: 326–330. doi: 10.1038/nbt936 PMID: 14758366

25. Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen. 1999; 4: 67–73. PMID: 10838414

26. Flint M, Logvinoff C, Rice CM, McKeating JA. Characterization of infectious retroviral pseudotype particles bearing hepatitis C virus glycoproteins. J Virol. 2004; 78: 6875–6882. doi: 10.1128/JVI.78.13.6875-6882.2004 PMID: 15194763

27. Pelkmans L, Helenius A. Endocytosis via caveolae. Traffic. 2002; 3: 311–320. PMID: 11967125

28. Radhakrishna H, Donaldson JG. ADP-ribosylation factor 6 regulates a novel plasma membrane recycling pathway. J Cell Biol. 1997; 138: 49–61. PMID: 9314528

29. Radhakrishna H, Klausner RD, Donaldson JG. Aluminum fluoride stimulates surface protrusions in cells overexpressing the ARF6 GTPase. J Cell Biol. 1996; 134: 935–947. PMID: 8769418

30. Sit ST, Manser E. Rho GTPases and their role in organizing the actin cytoskeleton. J Cell Sci. 2011; 124: 679–683. doi: 10.1242/jcs.064964 PMID: 21321325

31. Mercer J, Helenius A. Virus entry by macropinocytosis. Nat Cell Biol. 2009; 11: 510–520. doi: 10.1038/ncb0509-510 PMID: 19404330

32. Owen DJ, Collins BM, Evans PR. Adaptors for clathrin coats: structure and function. Annu Rev Cell Dev Biol. 2004; 20: 153–191. doi: 10.1146/annurev.cellbio.20.010403.104543 PMID: 15473838

33. McNulty S, Flint M, Nichol ST, Spiropoulos CF. Host mTORC1 signaling regulates Andes virus replication. J Virol. 2013; 87: 912–922. doi: 10.1128/JVI.02415-12 PMID: 23135723

34. von Kleist L, Stahlschmidt W, Bulut H, Gromova K, Puchkov D, Robertson MJ, et al. Role of the clathrin terminal domain in regulating coated pit dynamics revealed by small molecule inhibition. Cell. 2011; 146: 471–484. doi: 10.1016/j.cell.2011.06.025 PMID: 21816279

35. Koivusalo M, Welch C, Hayashi H, Scott CC, Kim M, Alexander T, et al. Amiloride inhibits macropinocytosis by lowering submembranous pH and preventing Rac1 and Cdc42 signaling. J Cell Biol. 2010; 188: 547–563. doi: 10.1083/jcb.200908086 PMID: 20156964

36. Hetzenecker S, Helenius A, Krzyzaniak MA. HCMV induces macropinocytosis for host cell entry in fibroblasts. Traffic. 2016; 17: 351–368. doi: 10.1111/tra.12355 PMID: 26650385

37. Raghu H, Sharma-Walia N, Veettil MV, Sadagopan S, Chandran B. Kaposi’s sarcoma-associated herpesvirus utilizes an actin polymerization-dependent macropinocytic pathway to enter human dermal microvascular endothelial and human umbilical vein endothelial cells. J Virol. 2009; 83: 4895–4911. doi: 10.1128/JVI.02498-08 PMID: 19279100

38. Liu NQ, Lossinsky AS, Popik W, Li X, Gjuliuva C, Kriederman B, et al. Human immunodeficiency virus type 1 enters brain microvascular endothelia by macropinocytosis dependent on lipid rafts and the mitogen-activated protein kinase signaling pathway. J Virol. 2002; 76: 6689–6700. doi: 10.1128/JVI.76.13.6689-6700.2002 PMID: 12050382

39. sieczkarski SB, Whittaker GR. Influenza virus can enter and infect cells in the absence of clathrin-mediated endocytosis. J Virol. 2002; 76: 10455–10464. doi: 10.1128/JVI.76.20.10455-10464.2002 PMID: 12239322

40. Krzyzaniak MA, Zumstein MT, Gerez JA, Picotti P, Helenius A. Host cell entry of respiratory syncytial virus involves macropinocytosis followed by proteolytic activation of the F protein. PLoS Pathog. 2013; 9: e1003309. doi: 10.1371/journal.ppat.1003309 PMID: 23593008
42. Lozach PY, Mancini R, Bitto D, Meier R, Oestereich L, Overby AK, et al. Entry of bunyaviruses into mammalian cells. Cell Host Microbe. 2010; 7: 488–499. doi: 10.1016/j.chom.2010.05.007 PMID: 20542252

43. Caswell P, Norman J. Endocytic transport of integrins during cell migration and invasion. Trends Cell Biol. 2008; 18: 257–263. doi: 10.1016/j.tcb.2008.03.004 PMID: 18456497

44. De Franceschi N, Hamidi H, Alanko J, Sahgal P, Ivaska J. Integrin traffic—the update. J Cell Sci. 2015; 128: 839–852. doi: 10.1242/jcs.161653 PMID: 25663697

45. Shin SY, Lee KS, Choi YK, Lim HJ, Lee HG, Lim Y, et al. The antipsychotic agent chlorpromazine induces autophagic cell death by inhibiting the Akt/mTOR pathway in human U-87MG glioma cells. Carcinogenesis. 2013; 34: 2080–2089. doi: 10.1093/carcin/bgt169 PMID: 23689352

46. Hussein IT, Cheng E, Ganaie SS, Werle MJ, Sheema S, Haque A, et al. Autophagic clearance of Sin Nombre hantavirus glycoprotein Gn promotes virus replication in cells. J Virol. 2012; 86: 7520–7529. doi: 10.1128/JVI.07204-11 PMID: 22553339

47. Mercer J, Schelhaas M, Helenius A. Virus entry by endocytosis. Annu Rev Biochem. 2010; 79: 803–833. doi: 10.1146/annurev-biochem-060208-104626 PMID: 20196649

48. Lagana A, Vadnais J, Le PU, Nguyen TN, Laprade R, Nabi IR, et al. Regulation of the formation of tumor cell pseudopodia by the Na(+)/H(+) exchanger NHE1. J Cell Sci. 2000; 113: 3649–3662. PMID: 11017880

49. Yu DH, Ban FO, Zhao M, Lu Q, Lovell JF, Bai F, et al. The use of nanoparticulate delivery systems in metronomic chemotherapy. Biomaterials. 2013; 34: 3925–3937. doi: 10.1016/j.biomaterials.2013.02.017 PMID: 23465835